2023
CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma
Noble J, Locke F, Savid-Frontera C, Jain M, Turner J, Miranda J, Madanayake T, Naderinezhad S, Corallo S, Menges M, Reid K, Robinson T. CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma. Blood 2023, 142: 3506. DOI: 10.1182/blood-2023-185074.Peer-Reviewed Original ResearchNon-durable responseProgression free survivalSurface protein expressionB-cell acute lymphoblastic leukemiaCAR-TCAR-T treatmentFlow cytometryProtein expressionFree survivalCell linesWestern blottingRefractory diffuse large B-cell lymphomaMedian expressionChimeric antigen receptor T cellsJeKo-1Associated with progression free survivalDiffuse large B-cell lymphomaPre-treatment tumor biopsiesPre-treatment tumor samplesLarge B-cell lymphomaIntron 2CAR-T failureCD19 surface expressionR/R DLBCL patientsIntron 6
2021
Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome
Rishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass D, Ahmed K. Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s123. DOI: 10.1016/j.ijrobp.2021.07.281.Peer-Reviewed Original ResearchImmune cell infiltratesProgression-free survivalAffected overall survivalOverall survivalHelper T cellsRadiosensitivity indexCell infiltrateClinical trialsT cellsPrimary GBMMedian progression-free survivalLack of monocytesNLR/PLRHigh expressionPoor prognostic factorCurrent smoking statusKaplan-Meier estimatesLog-rank testLow-grade gliomasMATERIAL/METHODSAssociation of factorsICI subtypesRGBM patientsAdjuvant radiotherapyFree survival